Celyad Oncology SA (0QFK.L)

0,3680 -0,0010 (-0,27%) Alla chiusura: 04:50PM BST

Celyad Oncology SA

Axis Business Park
Rue Edouard Belin 2
Mont-Saint-Guibert 1435
Belgium
32 1 039 41 00
https://www.celyad.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 17

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME	Co-Founder, Interim CEO & Executive Director	94,31k	N/D	1956
Mr. David Georges	Vice President of Finance & Administration	N/D	N/D	1976
Sara Zelkovic	Communications & Investor Relations Director	N/D	N/D	N/D
Ms. An Phan	Head of Legal	N/D	N/D	1975
Mr. Hannes Iserentant	Head of Intellectual Property	N/D	N/D	1978
Mr. Eytan Breman	Head of R&D	N/D	N/D	1980
Mr. Philippe Dechamps	Corporate Secretary	N/D	N/D	1970

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

Governance aziendale

L'ISS Governance QualityScore di Celyad Oncology SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.